$Biogen(BIIB.US)$ In a regulatory filing on Thursday, Samsung BioLogic...
$Biogen(BIIB.US)$ In a regulatory filing on Thursday, Samsung BioLogics denied earlier reports that Samsung Group was in talks to acquire U.S. drugmaker Biogen Inc., which was in the spotlight on Wednesday after shares of the drugmaker surged during intraday trading following a report by the Korea Economic Daily, which cited investment banking sources. The report said Biogen approached Samsung to buy its shares in a deal that could be valued at more than $42 billion.
Biogen's stock closed up 9.46% to $258.31 per share.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1 Comment · 13K Views
QianmengYu : it’s too early to say anything. Also it won’t be sansung biologics to purchase but the group level. anyway, it provides a pricing reference.